Mbarara University Of Science And Technology

Mbarara University of Science and Technology Faculty of Medicine Division, a state-controlled educational institution based in Mbarara, Uganda, receives federal research grants as a prime recipient and subrecipient, conducting health sciences research in infectious disease, non-communicable disease, implementation science, and clinical outcomes across multiple NIH institutes and centers.

The university operates almost entirely in a subrecipient capacity, with 72% of its 79 federal awards coming as sub-awards under prime grantee leadership from U.S. research institutions. Its 28% prime-recipient footprint consists almost exclusively of federal research grants rather than federal contracts. The institution has no federal contract vehicles or IDVs; all prime work flows through NIH and other health research grant programs administered as project grants and cooperative agreements. Award volume has grown from six grants in 2022 to a peak of twenty-three in 2024, with fifteen in 2025 and six to date in 2026, reflecting sustained but recently moderating growth in federal research partnership activity.

The National Institutes of Health dominates the customer base, accounting for the vast majority of awards across five constituent institutes. The National Institute on Alcohol Abuse and Alcoholism leads by count with seventeen awards, followed by the National Institute of Allergy and Infectious Diseases (fifteen awards), the Fogarty International Center (eleven awards), the National Institute of Child Health and Human Development (seven awards), and the National Cancer Institute (six awards). These five institutes represent 71% of all awards. The Fogarty International Center funds capacity-building and training grants under programs including CFDA 93.989 (International Research and Research Training); NIAAA, NIAID, and NICHD fund implementation science, clinical trials, and translational research ranging from behavioral interventions to diagnostic technologies.

Representative prime-grant work includes a $1.235 million NIAID award (CFDA 93.855, Allergy and Infectious Diseases Research) issued June 10, 2026, to conduct a Phase III randomized controlled trial on factory-treated, long-lasting permethrin-treated baby wraps for malaria prevention in children, running through May 31, 2031. The institution also leads a Fogarty K43 Emerging Global Leader award on pericoronary adipose tissue and subclinical coronary artery disease in people with HIV, aimed at developing faculty researcher expertise in innovative imaging techniques for HIV-related cardiovascular disease in sub-Saharan Africa. Other prime grants include implementation science research on WHO suicide prevention frameworks in rural Uganda (NIMH, July 1, 2024, through April 30, 2027) and a cooperative agreement with Fogarty on the Mbarara University Data Science Research Hub, leveraging machine learning and medical imaging for clinical applications across the region.

In its subrecipient role, MUST serves as the Uganda-based implementation and data-collection site for federally funded research led by U.S. academic medical centers and research universities. The institution functions as the on-the-ground partner for prospective cohort studies, randomized controlled trials, and diagnostic validation work, typically managing local recruitment, participant follow-up, specimen collection, regulatory compliance, data management, and staff supervision. Recent subgrant activity spans HIV disclosure interventions (Brigham & Women's Hospital, October 2025); cervical cancer screening with AI-supported image analysis and CRISPR-based diagnostics (Massachusetts General Hospital, December 2025); tuberculosis drug-adherence interventions using mobile money (Boston Medical Center, October 2025); and cognitive impairment and dementia epidemiology among people living with HIV (Massachusetts General Hospital, May 2026). MUST also collaborates on biodiversity field surveys in Ugandan forests as part of an NSF-funded wildlife zoonosis study led by UC Davis (August 2024) and on neural tube defect genetics research partnering with Duke University (July 2023).

The institution's research profile centers on HIV and acquired immunodeficiency, tuberculosis and respiratory disease, mental health and suicide prevention, non-communicable disease implementation science, maternal and child health, and emerging diagnostic and imaging technologies adapted for resource-limited settings in sub-Saharan Africa. Work emphasizes partnerships with U.S. academic medical centers, implementation science frameworks, and training and capacity-building for Ugandan clinician-scientists and health professionals. Six awards carry ultimate completion dates within the next twenty-four months, representing modest near-term recompete activity. MUST maintains a dedicated Grants Office responsible for financial administration, human resources, regulatory compliance, and data management for all federally funded research conducted through the institution.